Viva Biotech Revenues Surge on Move Into Contract Drug Manufacturing
Two key acquisitions last fall helped fuel fivefold rise in first-half revenue, as company swung back into profitability Key Takeaways: Viva Biotech’s fivefold jump in first-half revenues and move back…
RELATED ARTICLES
-
Bye bye Bossini? Faded clothing retailer gets a buyout offer
0933.HK 0592.HK 2331.HK -
After a failed Fosun buyout, what’s next for drug maker Henlius Biotech?
2696.HK
-
Everest Medicines eyes mRNA tumor vaccines as drug valuations rebound
1952.HK
- Cancer drug maker Genfleet joins Hong Kong IPO influx
-
Cancer drug maker Biostar shines on Hong Kong market debut
2563.HK
-
Zhengye Biotech’s ‘pet-sized’ IPO leaves plenty of room for more fundraising
ZYBT.US
- As Covid drug cash dwindles, Vigonvita targets new remedies
